Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia.

Abstract

Oxiracetam is a recently synthesized nootropic that was tested as a potential treatment for cognitive decline in patients with multi-infarct dementia (MID) and primary degenerative dementia (PDD). Subjects were 34 MID patients and 39 PDD patients who met entrance criteria for the study. A repeated measures ANOVA showed significant improvement in both patients with MID and patients with PDD for word fluency. The total score on the Relatives' Assessment of Global Symptomatology-Elderly showed significant improvement for patients with PDD. The average score on the Instrumental Activities of Daily Living Scale, however, showed a significant decline for patients with PDD.

• Authors: M W Dysken, R Katz, F Stallone, M Kuskowski
• Journal: The Journal of neuropsychiatry and clinical neurosciences (J Neuropsychiatry Clin Neurosci) Vol. 1 Issue 3 Pg. 249-52 ( 1989) ISSN: 0895-0172 [Print] United States
• PMID: 2521069 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Psychotropic Drugs
• Pyrrolidines
• oxiracetam

Topics

• Activities of Daily Living (psychology)
• Aged
• Aged, 80 and over
• Dementia (drug therapy, psychology)
• Dementia, Multi-Infarct (drug therapy, psychology)
• Dose-Response Relationship, Drug
• Female
• Humans
• Male
• Middle Aged
• Neuropsychological Tests
• Psychotropic Drugs (therapeutic use)
• Pyrrolidines (therapeutic use)